Welcome to our dedicated page for APOLLOMICS news (Ticker: APLM), a resource for investors and traders seeking the latest updates and insights on APOLLOMICS stock.
Apollomics Inc. reports developments as a clinical-stage biopharmaceutical company focused on oncology drug candidates for difficult-to-treat and treatment-resistant cancers. Its recurring updates center on vebreltinib (APL-101), a selective c-Met inhibitor being developed for non-small cell lung cancer and other tumors with c-Met alterations, along with pipeline assets that include targeted therapies, immuno-oncology candidates and other novel oncology mechanisms.
Company news also covers financial results, financing actions, collaborations for development and commercialization, board and committee changes, auditor and listing-status matters, operational continuity, and litigation-related resolutions. These updates connect Apollomics' clinical programs with its cash resources, governance, public-market status and partner agreements.
Apollomics, a clinical-stage biopharmaceutical company focusing on oncology drug candidates, will present at the 2024 BIO International Convention. The event will take place from June 3-6, 2024, in San Diego, California.
Apollomics' presentation, led by President Sanjeev Redkar, PhD, is scheduled for June 4 at 3:15 p.m. in Theater 2, Hall A, at the San Diego Convention Center.
Management will also be available for one-on-one meetings with registered attendees, which can be scheduled through the BIO One-on-One Partnering™ system or by contacting the provided email.
Apollomics Inc. (Nasdaq: APLM) announced a private placement financing of approximately $6 million through subscription agreements for a PIPE financing, with gross proceeds to fund pipeline programs and general corporate purposes. The financing involves the sale of 19,166,666 Class A ordinary shares at $0.30 per share, expected to close on May 8, 2024. Additionally, Dr. Robert Lin, M.D., Ph.D., an experienced physician and researcher, has been appointed to the board of directors, while Jonathan Wang, Ph.D., has resigned. Canaccord Genuity acts as the financial advisor for the financing.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.